Complete response to avelumab and IL-15 superagonist N-803 with Abraxane in Merkel cell carcinoma: a case study Oct 4, 2020 | Merkel Cell Carcinoma
PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations May 20, 2020 | Non-Small Cell Lung Cancer, Triple Negative Breast Cancer
Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist. Apr 16, 2020 | Merkel Cell Carcinoma, Non-Small Cell Lung Cancer
Overcoming hypoxia-induced functional suppression of NK cells Apr 8, 2020 | Non-Small Cell Lung Cancer, Triple Negative Breast Cancer
